Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Rui Hua Xu,Hendrik-Tobias Arkenau,Yung-Jue Bang,Crystal S. Denlinger,Ken Kato,Josep Tabernero,Jin Wang,Jiang Li,Henry Castro,Markus Moehler

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

2020

Rui Hua Xu
Hendrik-Tobias Arkenau
Yung-Jue Bang
Crystal S. Denlinger
Ken Kato
Josep Tabernero
Jin Wang
Jiang Li
Henry Castro
Markus Moehler

TPS458Background: First-line standard of care in patients with locally advanced or metastatic G/GEJ adenocarcinoma is fluoropyrimidine- and platinum (plat)-based combination chemotherapy. Despite i...

Keywords:

first line therapy
Gastroenterology
Adenocarcinoma
Gastroesophageal Junction
Internal medicine
Medicine
Placebo
Chemotherapy
Pathology
in patient
locally advanced
combination chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations